Innate Pharma to Attend June 2024 Investor Conferences


Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a global biotech company focused on developing innovative immunotherapies, today announced its participation in several prestigious investor conferences throughout June 2024. The company’s executive team will engage with investors, analysts, and industry leaders to discuss Innate Pharma’s latest advancements and future prospects.

Key conferences include the Goldman Sachs Annual Global Healthcare Conference in Los Angeles, the Jefferies Healthcare Conference in New York City, and the European Biotech Investor Day in London. During these events, Innate Pharma will present its robust pipeline of novel immunotherapy candidates targeting various cancer indications and highlight recent clinical trial successes.

Innate Pharma remains committed to revolutionizing cancer treatment through its cutting-edge research and development efforts. The company’s participation in these high-profile conferences underscores its dedication to driving innovation and creating value for patients and shareholders alike.